Clene Inc. Stock Price, News, Quote & History

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Clene Inc.

Clene to Present at the Emerging Growth Conference

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

NanoXplore Inc.

Cybin Inc.

Latest News

New Discoveries Reinforces District Potential at Joaquin

OPAL Fuels Reports Third Quarter 2025 Results

Doubleview Gold Corp. Closes First Tranche of $5,700,000 Non-Brokered Private Placement

Aura Minerals Announces Exercise of Warrants in Altamira Gold Corp.

Entitlement Offer raises $2.42M

Latest News

Outlook Reports

Featured Stocks

Browse Companies